---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-310588"
form_type: "8-K"
ticker: "SRPT"
cik: "0000873303"
company_name: "Sarepta Therapeutics, Inc."
filed_at: "2025-12-08T23:59:59+00:00"
generated_at: "2026-05-16T14:09:59.529024+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Sarepta grants CEO Ingram $12M equity awards after 8-year gap

## Summary
- CEO Douglas Ingram granted ~$12M total equity: ~$6M time-based RSUs vesting over 3 years and ~$6M performance-based awards tied to Incentive EBITDA for 2026-2027.
- Performance awards can pay out 0-200% of target; vesting subject to 3-year service period from Dec 7, 2025.
- First equity grant for Ingram since 2017; previously deferred consistent with employment agreement.
- Performance condition based on cumulative Incentive EBITDA over two-year period ending Dec 31, 2027.
- Up to 269,542 shares at target across four award types (RSUs, units, restricted shares, performance shares).

## SEC filing metadata
- accession: 0001193125-25-310588
- form_type: 8-K
- ticker: SRPT
- cik: 0000873303
- company_name: Sarepta Therapeutics, Inc.
- filed_at: 2025-12-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/873303/000119312525310588/0001193125-25-310588-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/873303/000119312525310588/d15497d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-310588
- JSON: https://secwatch.observer/filing/0001193125-25-310588.json
- Plain text: https://secwatch.observer/filing/0001193125-25-310588.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.